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Antimicrobial Drug Resistance in Taiwan
Shio-Shin Jean,1 Po-Ren Hsueh2,3*
Antimicrobial resistance is a major global health threat associated with high mortality rates and high medical
costs. Geographic variations in resistance profiles of bacterial and fungal pathogens have had a considerable
impact on antimicrobial prescription. In Taiwan, there is an alarmingly high prevalence of penicillin-resistant
Streptococcus pneumoniae, multidrug-resistant and extensively drug-resistant (XDR) Pseudomonas aeruginosa
and Acinetobacter baumannii, extended-spectrum β-lactamase-producing Klebsiella pneumoniae, penicillin- and
fluoroquinolone-resistant Neisseria gonorrhoeae, and azole-resistant Candida species. In addition, the emer-
gence of XDR Mycobacterium tuberculosis has illustrated the need for regular monitoring of the resistance
profiles of clinical isolates. A few clones of XDR A. baumannii and methicillin-resistant Staphylococcus aureus
of unique sequence type (ST 59) have disseminated in Taiwanese hospital settings. Besides, the existence of
a transposon-harboring carbapenemase gene has been verified in XDR P aeruginosa strains throughout
Taiwan. An end to the worsening trends in the emergence of antimicrobial resistance will require continu-
ous survey of resistance data from clinical isolates and effective implementation of strict infection control
policies in healthcare settings and animal husbandry.
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Antimicrobial resistance is a persistent world-
wide healthcare concern. However, in comparison
with Western countries, in Asia there are con-
siderable geographic variations in the resistance
of various bacterial and fungal pathogens. In
North America and Europe, community-acquired
methicillin-resistant Staphylococcus aureus (MRSA),1
vancomycin-resistant enterococci (VRE),2 Klebsiella
pneumoniae carbapenemase (KPC)-producing 
K pneumoniae,3 multidrug-resistant (MDR)
Acinetobacter species,4,5 and fluoroquinolone- and 
carbapenem-resistant Pseudomonas aeruginosa5 have
been reported and are widespread in hospital
settings. In contrast, Taiwan has strikingly high pre-
valence of penicillin-resistant Streptococcus pneumo-
niae,6 extensively drug-resistant (XDR) Acinetobacter
baumannii (15%),7 extended-spectrum β-lactamase
(ESBL)-producing K pneumoniae (26%),8 fluoro-
quinolone-resistant Neisseria gonorrhoeae,9 MDR
Salmonella enterica serotype Choleraesuis,10,11
azole-resistant Candida species (particularly,
Candida glabrata),12 and the emergence of XDR
©2011 Elsevier & Formosan Medical Association
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1Departments of Intensive Care and Internal Medicine, Min-Sheng General Hospital, Taoyuan, Departments of 2Laboratory
Medicine and 3Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Received: June 9, 2010
Revised: July 19, 2010
Accepted: August 3, 2010
*Correspondence to: Dr Po-Ren Hsueh, Department of Laboratory Medicine, National Taiwan
University Hospital, 7 Chung-Shan South Road, Taipei 100, Taiwan.
E-mail: hsporen@ntu.edu.tw
Antimicrobial resistance in Taiwan
J Formos Med Assoc | 2011 • Vol 110 • No 1 5
Mycobacterium tuberculosis (XDRTB).13 The emer-
gence of these resistant species has caused enor-
mous difficulty in managing MDR clinical
infections and preventing their dissemination. This
paper reviews the resistance profiles of the most im-
portant bacterial and fungal pathogens in Taiwan.
MRSA
Infections caused by MRSA are troublesome be-
cause of the high degree of difficulty of eradication
and limited antimicrobial treatment options. In
a medical center in Northern Taiwan (National
Taiwan University Hospital, NTUH), MRSA ac-
counted for 74% of all nosocomial S aureus
isolates in 2000.14 A longitudinal survey of the
prevalence of methicillin resistance in healthcare-
associated S aureus isolates in NTUH from 1986
through 2009 (Figure 1) found that the propor-
tion of MRSA far exceeded that of methicillin-
susceptible isolates after 1996, but this difference
then declined markedly after 2007. Many new
antibiotic options for the management of MRSA
infections have become available in the present
decade.15 However, because of the long-term use of
virginiamycin in animal husbandry, quinupristin–
dalfopristin had a high non-susceptibility rate
(> 30%) to MRSA strains before its launch in
Taiwan.16 Consequently, this agent is not a suit-
able choice for the management of Taiwanese
MRSA infections. Although few Taiwanese MRSA
strains have exhibited in vitro vancomycin hetero-
resistance,17 their clinical significance and actual
prevalence needs to be further evaluated.
In addition to nosocomially acquired MRSA,
the emergence of community-acquired (CA)-MRSA
has also been reported worldwide.1 By compari-
son with healthcare-associated MRSA infections,
CA-MRSA infections are more likely to involve
the skin and soft-tissue1 and to present as necro-
tizing pneumonia, especially when caused by iso-
lates that carry the Panton-Valentine leukocidin
genes.18 In a survey by Vandenesch et al, geneti-
cally diverse CA-MRSA strains collected outside
of Taiwan were noted to share a type IV SCCmec
cassette, with susceptibility to most antibiotics.1
Distinct from the findings of foreign surveys, how-
ever, some CA-MRSA isolates in Northern Taiwan
harbored type V SCCmec,19 with the major clone
having sequence type (ST) 59 detected by the
multilocus sequence typing method.20 Although
the inappropriate use of empirical antibiotics
against CA-MRSA infections appears not to have
had a significant impact on mortality,19,20 timely
surgery and monitoring of future changes of 
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Figure 1. Annual rates of methicillin-resistant Staphylococcus aureus among all S aureus isolates from patients with
healthcare-associated infection at National Taiwan University Hospital, 1986–2009. MSSA = methicillin-susceptible 
S aureus; MRSA = methicillin-resistant Staphylococcus aureus.
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antimicrobial non-susceptibility of CA-MRSA iso-
lates are still indicated.
S pneumoniae and Haemophilus influenzae
Antimicrobial resistance of S pneumoniae and 
H influenzae, two core organisms that cause 
community-acquired pneumonia and pyogenic
meningitis, is a worldwide concern.21,22 In a longi-
tudinal surveillance of trends in non-susceptibility
to penicillin and erythromycin in clinical S pneu-
moniae isolates from 1984 to 2009 in NTUH
(Figure 2), > 70% of pneumococci exhibited per-
sistent non-susceptibility to these two important
antimicrobials from 1998. In addition, inves-
tigation of important pathogens from intensive
care units (ICUs) in Taiwan (SMART; Surveil-
lance of Multicenter Antimicrobial Resistance in
Taiwan) in 2005 has revealed high rates of non-
susceptibility to penicillin (85%), ceftriaxone
(66%), and cefepime (57%) against S pneumoniae,
evaluated by the meningitis criteria.6 In addition,
a significantly increasing prevalence of penicillin-
non-susceptible S pneumoniae and ceftriaxone-
non-susceptible S pneumoniae strains has also been
found between 2000 and 2005 (p < 0.05).6,23 As
a result of the high likelihood of penicillin-non-
susceptible S pneumoniae exhibiting co-resistance
to many non-β-lactam antimicrobials,24 institu-
tion of stricter control policies for prescription of
β-lactams is mandatory. Similarly, although no
β-lactamase-negative ampicillin-resistant H in-
fluenzae strain was detected in SMART 2005, high
non-susceptibility of H influenzae to ampicillin
(55%) and cefaclor (45%) was demonstrated.6
Besides, alertness to the high non-susceptibility
rates for imipenem, trimethoprim–sulfamethox-
azole, and clarithromycin against ICU H influenzae
strains (16%, 64%, and 68%, respectively) is re-
quired when selecting therapy.6 Tigecycline exerts
good in vitro activity against S pneumoniae and 
H influenzae isolates, with the minimum inhib-
itory concentration required to inhibit the growth
of 90% of organisms (MIC90) being 0.03 and
0.25 μg/mL, respectively, which was in accordance
with those previously reported.6,25 Among S pneu-
moniae isolates, resistance to commonly used res-
piratory fluoroquinolones (such as moxifloxacin
and levofloxacin) has remained low (resistance
rate < 5%), and tigecycline has exerted potent 
in vitro activity against the isolates tested.6
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Figure 2. Trends of non-susceptibility to penicillin and erythromycin among clinical isolates of Streptococcus pneumo-
niae as determined by the disk diffusion method at National Taiwan University Hospital, 1984–2009.
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VRE
Enterococci that exhibit resistance to vancomycin
have been a great problem in the present decade.2
Patients with VRE bloodstream infection have
been shown to have a higher mortality rate than
those with vancomycin-susceptible enterococcal
bacteremia (odds ratio: 2.52).26 In addition, nos-
ocomial and inter-hospital dissemination of some
VRE clones with long-term persistence has been
reported in many countries.27,28 Longitudinal sur-
veillance (1996–2009) of annual rates of entero-
cocci with resistance to vancomyin in NTUH
(Figure 3) has revealed a gradually rising prevalence
of VRE. Clonal spread of CC17 VRE (Enterococcus
faecium) with multilocus sequence type 78 (ST78)
and a novel ST444 has been reported in Taiwan.29
These findings indicate the need for early detec-
tion and further prevention of spread of VRE in
healthcare settings.
S enterica serotype Choleraesuis
S enterica serotype Choleraesuis, unlike other
non-typhoidal Salmonella, is a frequent cause of
septicemic episodes, which may involve mycotic
aneurysm and osteomyelitis.10,30 The MDR pheno-
type (defined as resistance to ampicillin, chloram-
phenicol, and trimethoprim–sulfamethoxazole)
among Taiwanese S enterica serotype Cholerae-
suis has been reported.31 Characteristically, the
rapidly increasing prevalence of ciprofloxacin-
resistant S Choleraesuis, which shares an identical
pulsotype with that of swine isolates, is a note-
worthy problem in our country.30,32 In the latest
Asian joint survey of non-typhoid Salmonella,11
the prevalence of reduced susceptibility (MIC:
0.125–1.0 μg/mL) and absolute resistance (MIC
≥ 4 μg/mL) to ciprofloxacin in Taiwanese S
Choleraesuis isolates was 61.5% and 30.1%, re-
spectively. In contrast to overall non-typhoidal
strains, the prevalence of reduced susceptibility
to ceftriaxone (MIC: 2–8 μg/mL) for S Chol-
eraesuis isolates in Taiwan was markedly low
(38% vs. 10%).11,33 Imipenem appears to be ef-
fective for treatment of tenaciously cefotaxime-
and ciprofloxacin-resistant S Choleraesuis infec-
tion.34 Periodic monitoring of the antimicrobial
utilization in animal husbandry and of the evo-
lutionary trends of resistance to fluoroquinolones
and ceftriaxone in MDR S Choleraesuis provides
essential information for the selection of appro-
priate therapy.
K pneumoniae and Escherichia coli
The K pneumoniae isolates in Taiwan, with viru-
lence genes including rmpA and magA, are known
to cause many metastatic infections.35 In addition,
the rapidly rising prevalences of ESBL produc-
tion among E coli (14% in 2005) and K pneumo-
niae (11% in 2000, and 26% in 2005, p = 0.002)
isolates in ICUs in Taiwan are also a notable
focus of resistance.8,23 K pneumoniae is also the
most likely pathogen to produce ESBL among
Enterobacteriaceae isolated in the ICU.8 In an in-
vestigation in the Asia–Pacific region, the noso-
comially acquired (≥ 48 hours) intra-abdominal
K pneumoniae isolates were shown to have a sig-
nificantly higher probability of producing ESBLs
than CA ones.36 Owing to the high ESBL pre-
valence (which also contributes the high pos-
sibility of non-susceptibility to ciprofloxacin37)
in K pneumonia and E coli, the third-generation
cephalosporins and fluoroquinolones are not
optimal choices against nosocomial K pneumo-
niae infections,8 and carbapenems are some of
the most effective agents against nosocomial 
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Figure 3. Annual rates of vancomycin-resistant enterococci
among all enterococcal isolates from patients with healthcare-
associated infection at National Taiwan University Hospital,
1996–2009. VRE = vancomycin-resistant enterococci.
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K pneumoniae.8,36 However, the emergence of
profoundly high MIC90s for meropenem and 
ertapenem (2 μg/mL and 8 μg/mL, respectively)
against Taiwanese ESBL-producing K pneumoniae
strains has also demonstrated the need for close
monitoring of the evolution of their resistance.38
The tigecycline MIC90s for overall K pneumoniae
isolates collected in SMART 2005, and ESBL-
producing K pneumoniae strains collected in TIST
(Tigecycline in-vitro Surveillance in Taiwan, 2006–
07), were all 2 μg/mL.8,39 However, in one in vitro
susceptibility study among intra-abdominal ESBL-
producing K pneumoniae isolates, 17% (4/24) ex-
hibited tigecycline MIC levels ≥ 2 μg/mL.40 Due to
its bacteriostatic mechanism and relatively low
serum concentration (< 1 μg/mL, sampled after at
least 6 doses with standard-dose administration),41
prudent use of this valuable agent as an alterna-
tive to carbapenems should be considered.
P aeruginosa
P aeruginosa is of great concern as a nosocomial
pathogen. It is notorious for having multiple
mechanisms of antimicrobial resistance (including
loss of the outer membrane protein, overexpres-
sion of multidrug efflux genes, interplay between
impermeability and certain β-lactamases, and
carbapenemases).42 Although the prevalence of
carbapenem-non-susceptible (CNS) P aeruginosa
was not as high as that of the CNS A baumannii in
SMART 2005 data,7 horizontal dissemination of
mobile Tn6001, which contains a blaVIM-3-harbor-
ing integron In450, has been reported in CNS
and XDR P aeruginosa strains collected from med-
ical centers throughout Taiwan.43 In addition,
data from SMART 2005 have shown that all (3/3)
XDR P aeruginosa strains (defined as resistant to
all common antipseudomonal agents except col-
istin) also exhibited non-susceptibility to col-
istin.7 A longitudinal survey of antimicrobial
resistance of clinical P aeruginosa isolates since
1999 in NTUH (Figure 4) has found a 
fluctuating annual prevalence of ciprofloxacin
non-susceptibility in P aeruginosa. Other investi-
gations have suggested that increased consump-
tion of levofloxacin is associated with the decline
of susceptibility to ciprofloxacin for P aeruginosa
isolates,44,45 which might partly explain this evolu-
tionary trend of ciprofloxacin resistance. Never-
theless, due to the recent lack of new effective
antipseudomonal agents and to avoid progression
of resistance, control of dissemination by specific
measures remains an important task.
A baumannii and other Acinetobacter species
Clinical infections caused by MDR A. baumannii
(defined as isolates resistant to ≥ 3 different classes
of antimicrobials) and Acinetobacter species have
been verified to culminate in high in-hospital at-
tributable (21.8%) and overall (26–60%) mor-
tality rates.4,46,47 For more than a decade, the
selection of appropriate antimicrobials and the
control of nosocomial infection caused by MDR
A baumannii have been persistent worldwide
problems.48,49 Multiple resistance mechanisms
may exist in a single Acinetobacter species.42 In
theory, hospital-acquired A baumannii as well as 
P aeruginosa are unlikely to present with markedly
different MDR antibiogram prevalence. However,
in contrast with P aeruginosa, clinical A bauman-
nii strains are more likely to exhibit an in vitro
MDR phenotype in Taiwan.7,48 Consequently, the
gradually rising prevalence of A baumannii that 
is resistant to imipenem (which are also usually
the MDR isolates), which is the main antibiotic
of last resort for critically ill patients, is an im-
portant focus that requires close monitoring in
Taiwan (22% in 2000 vs. 25% in 2005),7,23 as
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Figure 4. Annual rates of ciprofloxacin non-susceptibility
among Pseudomonas aeruginosa isolates from patients
with healthcare-associated infection at National Taiwan
University Hospital, 1999–2009.
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well as in other countries.50 In significant contrast
with non-baumannii Acinetobacter spp., the oxacilli-
nase (Ambler class D β-lactamase) genes, located
in plasmids and downstream to ISAba3 and
IS1008 (two promoters for the transcription 
control of blaOXA genes), have been demon-
strated to play an important role in conferring
non-susceptibility to imipenem for A baumannii
isolates in Taiwan.51,52 Besides, the class I inte-
gron that harbors the blaIMP-1 gene has been iden-
tified in a carbapenem-resistant clone in a
Southern Taiwanese medical center.53 These im-
pressive findings correspond temporally with the
alarming fact that intra-hospital clonal spread of
MDR A baumannii and inter-hospital dissemina-
tion of certain clones of XDR A baumannii (defined
as isolates resistant to all antimicrobial agents
except colistin or tigecycline) have been docu-
mented in major teaching hospitals in Taiwan.7,53
Although tigecycline was previously considered 
a promising agent against MDR- and colistin-
resistant A baumannii,54 Taiwanese ICU A bau-
mannii have a tigecycline MIC90 of 4 μg/mL,7
which is higher than that in Greece.54 Furthermore,
virtually all of the colistin-resistant A baumannii
strains in SMART 2005 also exhibited non-
susceptibility to tigecycline.7 A few reports have
suggested that the combination of some antibi-
otics would exert in vitro synergistic effects against
MDR A baumannii.55,56 However, large-scale pros-
pective clinical surveys are needed to determine
whether combination therapy against this prob-
lematic pathogen is effective. Thus, strict infection
control policy remains of the utmost importance.
N gonorrhoeae
The annual number of new cases of confirmed
infection caused by N gonorrhoeae, one of the
pathogens of sexually transmitted diseases, has
shown a gradually increasing trend (from 7.1 in
2008 to 9.3 in 2009 per 100,000 population) in
Taiwan.57 In our country, the prevalence of peni-
cillin resistance in N gonorrhoeae was markedly
high (88.8%) before 1990.58 In addition, the rapid
upsurge of prevalence of ciprofloxacin resistance
in Northern Taiwan (87.5% in 2002, and 93.1%
in 2003) is alarming.9 The occurrence of multiple
(mostly > 2) mutations in the parA and gyrC gene
has been verified to confer prominent cipro-
floxacin resistance (MIC: 4 to ≥ 16 μg/mL) in 
N gonorrhoeae isolates.9 Besides, the resistance
mechanisms that mediate non-susceptibility to
other agents (including penicillin, tetracycline,
macrolides, and cefixime) have been elucidated
in the present decade.59,60 According to the in vitro
susceptibility of endemic surveys, ceftriaxone
should be seriously considered as one of the
first-line options with regard to the management
of gonorrhea in Taiwan.
M tuberculosis
Taiwan is an endemic country for M tuberculosis.
From the data provided by the Taiwan Surveillance
of Drug Resistance in Tuberculosis (TB), high resis-
tant rates against the first-line anti-TB drugs 
(including: 11.3% to isoniazid; 7.5% to rifampicin;
20.4% to any first-line agent, including isoniazid,
rifampicin, ethambutol, and pyrazinamide; and
5.3% MDR to both isoniazid and rifampicin)
were reported in 2004, which were higher than
those in a global survey (6.6%, 2.2%, 10.4%, and
1.7%, respectively).61,62 Fluoroquinolones are
often considered the preferred alternative agents
for managing drug-resistant TB. Nevertheless, a
study by Wang et al has suggested that any resis-
tance to first-line anti-TB agents or prior anti-TB
management was well-correlated with TB resis-
tance to fluoroquinolones.63 In addition, XDR-TB
(MDR isolates resistant to any fluoroquinolone
and ≥1 of the three injectable anti-TB drugs, capre-
omycin, kanamycin, and amikacin) has emerged
in Taiwan.13,61 In surveillance of the antimicrobial
non-susceptibility of XDR-TB isolates collected
in 2004–2005, the resistance rates to second-line
anti-TB drugs (including fluoroquinolone, kana-
mycin, ethionamide, and para-aminosalicylate)
exceeded 15%, and the fluoroquinolone resis-
tance rate among Taiwanese MDR strains was as
high as 42.8%.61 In the most recent Taiwanese
studies, about one-half of MDR- and XDR-TB
strains belonged to the Beijing family genotype,
by spoligotyping analysis,64 and most patients
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with XDR-TB infection had pulmonary cavitary
lesions and a previous history of anti-TB treat-
ment,13,64 which escalates the degree of difficulty
of successful eradication. To implement an effec-
tive infection control policy for prevention of the
dissemination of MDR- and XDR-TB, continuous
monitoring of their prevalence and prudent use
of fluoroquinolone agents are mandatory.
Candida species
Invasive candidiasis has emerged as an important
nosocomial infection, especially in critically ill
patients, who have crude mortality rates 5–10-fold
higher than those of the entire hospital popula-
tion, and may be as high as 60%.65,66 Although
there is a markedly different regional prevalence in
the etiology of invasive candidiasis in Asia-Pacific
countries,67 C albicans accounted for > 50% of in-
vasive isolates of Candida spp. in Taiwan, followed
by Candida tropicalis (18%), C glabrata (16%), and
Candida parapsilosis (10%).67 The fungemia caused
by C glabrata, which almost always occurs in pa-
tients with underlying comorbidity, and shows
high non-susceptibility to fluconazole (i.e. only
22% of organisms have MICs ≤ 8 μg/mL), presents
a considerable crisis in the selection of appropriate
therapy. Fortunately, it can be successfully man-
aged by echinocandins and new tri-azoles.12,68 In
contrast with invasive C glabrata strains, all of the
other three Candida spp. (collected from 1999 to
2007 in Northern Taiwan) have exhibited ≥ 95%
susceptibility to fluconazole.62 To decrease the
in-hospital mortality rate, regular surveillance of
the epidemiology and resistance load for can-
didiasis is crucial to determine the best treatment
options for all high-risk patients.
Conclusions
Many measures have been taken in our country
to reduce the heavy antimicrobial resistance load
and control its escalating trends. The Bureau of
National Health Insurance in Taiwan has imple-
mented a strict policy on antibiotic prescription
in hospitals and drug stores, especially for the
treatment of trivial upper respiratory tract infection
and inappropriate use in surgical prophylaxis. In
addition, the enhancement of hand-washing ma-
neuvers in healthcare settings and the establish-
ment of standards of practice for performance of
invasive procedures in hospitals have been widely
promoted. The Council of Agriculture in Taiwan
has prohibited the use of several antimicrobials
that were previously used as growth promoters
or prophylactic agents in animal husbandry over
the past three decades. This is predicted to result
in a decline of resistance of human pathogens that
originate from food-producing animals. Finally, to
provide timely revision of infection control pol-
icy, continued nationwide surveillance of anti-
microbial resistance remains a necessity in Taiwan.
These measures provide the best prospect of halt-
ing the rise of resistance as well as the requisite
information to encourage appropriate utilization
of antibiotics in specific patient populations, 
especially those who are critically ill.
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